PMID- 16542286
OWN - NLM
STAT- MEDLINE
DCOM- 20060410
LR  - 20131121
IS  - 0002-9270 (Print)
IS  - 0002-9270 (Linking)
VI  - 101
IP  - 3
DP  - 2006 Mar
TI  - Role of intravenous omeprazole in patients with high-risk peptic ulcer bleeding 
      after successful endoscopic epinephrine injection: a prospective randomized 
      comparative trial.
PG  - 500-5
AB  - BACKGROUND: Epinephrine injection is the most common endoscopic therapy for 
      peptic ulcer bleeding. Controversy exists concerning the optimal dose of proton 
      pump inhibitors (PPI) for patients with bleeding peptic ulcers after successful 
      endoscopic therapy. The objective of this study was to determine the optimal dose 
      of PPI after successful endoscopic epinephrine injection in patients with 
      bleeding peptic ulcers. METHODS: A total of 200 peptic ulcer patients with active 
      bleeding or nonbleeding visible vessels (NBVV) who had obtained initial 
      hemostasis with endoscopic injection of epinephrine were randomized to receive 
      omeprazole 40 mg infusion every 6 h, omeprazole 40 mg infusion every 12 h or 
      cimetidine (CIM) 400 mg infusion every 12 h. Outcomes were checked at 14 days 
      after enrollment. RESULTS: Rebleeding episodes were fewer in the group with 
      omeprazole 40 mg infusion every 6 h (6/67, 9%) as compared with that of the CIM 
      infusion group (22/67, 32.8%, p < 0.01). The volume of blood transfusion was less 
      in the group with omeprazole 40 mg every 6 h than in those groups with omepraole 
      40 mg infusion every 12 h (p= 0.001) and CIM 400 mg infusion every 12 h (p < 
      0.001). The hospital stay, number of patients requiring urgent operation, and 
      death rate were not statistically different among the three groups. CONCLUSION: A 
      combination of endoscopic epinephrine injection and a large dose of omeprazole 
      infusion is superior to combined endoscopic epinephrine injection with CIM 
      infusion for preventing recurrent bleeding from peptic ulcers with active 
      bleeding or NBVV.
FAU - Lin, Hwai-Jeng
AU  - Lin HJ
AD  - Division of Gastroenterology, Department of Medicine, VGH-TAIPEI, Sec. 2 Shih-Pai 
      Road, Taipei 11217, Taiwan.
FAU - Lo, Wen-Ching
AU  - Lo WC
FAU - Cheng, Yang-Chih
AU  - Cheng YC
FAU - Perng, Chin-Lin
AU  - Perng CL
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Am J Gastroenterol
JT  - The American journal of gastroenterology
JID - 0421030
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Proton Pump Inhibitors)
RN  - 80061L1WGD (Cimetidine)
RN  - KG60484QX9 (Omeprazole)
RN  - YKH834O4BH (Epinephrine)
SB  - IM
CIN - Am J Gastroenterol. 2006 Dec;101(12):2888-9; author reply 2889. PMID: 17227532
MH  - Adult
MH  - Aged
MH  - Anti-Ulcer Agents/*administration & dosage
MH  - Blood Transfusion
MH  - Cimetidine/administration & dosage
MH  - Drug Administration Schedule
MH  - Electrocoagulation
MH  - Epinephrine/*administration & dosage
MH  - Female
MH  - *Gastroscopy
MH  - Humans
MH  - Infusions, Intravenous
MH  - Injections, Intralesional
MH  - Male
MH  - Omeprazole/*administration & dosage
MH  - Peptic Ulcer Hemorrhage/*drug therapy/etiology
MH  - Prospective Studies
MH  - *Proton Pump Inhibitors
MH  - Recurrence
MH  - Risk Factors
EDAT- 2006/03/18 09:00
MHDA- 2006/04/11 09:00
CRDT- 2006/03/18 09:00
PHST- 2006/03/18 09:00 [pubmed]
PHST- 2006/04/11 09:00 [medline]
PHST- 2006/03/18 09:00 [entrez]
AID - AJG399 [pii]
AID - 10.1111/j.1572-0241.2006.00399.x [doi]
PST - ppublish
SO  - Am J Gastroenterol. 2006 Mar;101(3):500-5. doi: 10.1111/j.1572-0241.2006.00399.x.